CD274 and non-small cell lung carcinoma: Another meta-analysis found that anti–PD-1 was more effective than anti–PD-L1 as monotherapy in patients with metastatic and previously treated NSCLC [25] or as a first-line treatment for advanced squamous NSCLC combined with chemotherapy [26].